Core Viewpoint - The company has announced a specific stock issuance to certain parties, which may dilute immediate returns for existing shareholders, and has outlined measures to mitigate this impact [1][2][4]. Financial Impact Analysis - The company analyzed the impact of the stock issuance on key financial metrics, assuming a maximum issuance of 180 million shares and a total fundraising of 600 million yuan [2][3]. - The projected net profit for 2025, based on different growth scenarios (10% increase, flat, and 10% decrease), shows varying impacts on earnings per share and return on equity [4][5]. Risk of Dilution - Post-issuance, the company's total share capital and net asset scale will significantly increase, potentially leading to a decrease in return on equity if net profit growth does not keep pace with net asset growth [4][6]. Necessity and Rationality of Issuance - The issuance is deemed necessary to optimize capital structure, alleviate working capital pressure, and enhance market confidence, thereby improving the company's risk resilience [6][7]. Measures to Mitigate Dilution - The company will implement strict dividend policies to ensure shareholder returns, enhance marketing and customer service capabilities, and ensure legal and rational use of raised funds [7][8]. - A three-party supervision agreement will be established to oversee the use of raised funds, ensuring compliance with regulatory requirements [8][9]. Commitments from Key Stakeholders - The controlling shareholders and management have committed to not interfere with the company's operations and to uphold the interests of shareholders, with penalties for any breaches of these commitments [9][10]. Approval Process - The board of directors and supervisory board have approved the analysis and measures related to the dilution of immediate returns, with ongoing disclosures planned for the implementation of these measures [10][11].

Core Viewpoint - The company plans to issue A-shares to specific investors in 2025, which may dilute immediate returns for existing shareholders, but it has proposed measures to compensate for this dilution and ensure the protection of minority investors' rights [2][6][10]. Financial Impact Analysis - The company estimates a net profit range of -195 million to -157 million yuan for 2024, with a potential 50% increase in losses compared to 2024 [3][4]. - Three scenarios for 2025 net profit projections are analyzed: a 50% increase in losses, maintaining 2024 levels, and a 50% reduction in losses [4][5]. - The projected basic and diluted earnings per share (EPS) under these scenarios range from -0.90 to -1.36 yuan [4][5]. Necessity and Reasonableness of the Issuance - The issuance aligns with relevant policies and the company's strategic development plan, indicating its necessity and feasibility [6][7]. Use of Raised Funds - The raised funds will be allocated to "innovative drug R&D," "industrialization of traditional Chinese medicine," and "supplementing working capital," supporting the company's transition from generic drugs to innovative drugs and health consumption sectors [7][8][9]. Company’s Preparedness for Investment Projects - The company has accumulated significant experience and technical barriers in the liver health and antiviral sectors, with a strong talent pool and ongoing patent applications for its drug candidates [9]. Measures to Mitigate Dilution of Immediate Returns - The company will enhance its competitive advantages and profitability, actively implement fundraising projects, and strengthen fund management to mitigate the dilution of immediate returns for shareholders [10][11][12]. Commitments from Key Stakeholders - The company's board and senior management have committed to fulfilling the proposed compensation measures for shareholders, ensuring no unfair benefit is provided to other entities [14][15].

股票代码：600272 股票简称：开开实业 编号：2025—009 900943 开开 B 股 上海开开实业股份有限公司 关于公司 2024 年度向特定对象发行 A 股股票摊薄即期回报及 采取填补措施和相关主体承诺（修订稿）的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司（以下简称："公司"）于 2024 年 5 月 20 日召开的公司第十届董事会第十八次会议、第十届监事会第十二次会议， 于 2024 年 6 月 28 日召开的 2023 年年度股东大会，审议通过了关于公司 2024 年度向特定对象发行 A 股股票（以下简称"本次发行"）的相关议案。 （具体内容详见 2024 年 5 月 21 日、6 月 29 日《上海证券报》《香港商 报》和上海证券交易所网站 www.sse.com.cn 公告）。公司于 2025 年 2 月 28 日召开的公司第十届董事会第二十三次会议、第十届监事会第十六次 会议审议通过了《关于公司 2024 年度向特定对象发行 A 股股票摊薄即 期回报及采取填补措施和 ...

首次公开发行股票 上市公告书 保荐机构（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 股票简称：和泰机电 股票代码：001225 杭州和泰机电股份有限公司 HANGZHOU HOTA M&E HOLDINGS CO., LTD. （注册地址：萧山区宁围街道通惠北路 1201 号） 二〇二三年二月 1 特别提示 本公司股票将于 2023 年 2 月 22 日在深圳证券交易所主板上市。本公司提醒 投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市初期切忌 盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中简称或名词的释义与本公司首次公开发行股 票招股说明书释义相同。本上市公告书数值通常保留至小数点后两位，若出现总 数与各分项数值之和尾数不符的情况，均为四舍五入所致。 2 第一节 重要声明与提示 杭州和泰机电股份有限公司（以下简称"和泰机电"、"发行人"、"本公司"、 "公司"）股票将在深圳证券交易所上市。 本公司及全体董事、监事、高级管理人员保证上市公告书的真实性、准确性、 完整性，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法承担 法律责任。 深圳证券交 ...

合肥雪祺电气股份有限公司 Hefei Snowky Electric Co., Ltd. （安徽省合肥市经济技术开发区青鸾路 369 号） 首次公开发行股票并上市招股说明书 本公司的发行申请尚未得到中国证监会核准。本招股说明书（申报稿）不具 有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的 保荐机构（主承销商） （申报稿） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 招股说明书全文作为作出投资决定的依据。 合肥雪祺电气股份有限公司 首次公开发行股票并上市招股说明书 发行概况 | 发行股票类型： | 人民币普通股（A股） | | --- | --- | | 发行股数： | 不超过3,419万股 | | 占发行后总股本的比例： | 不低于25% | | 每股面值： | 人民币1.00元 | | 每股发行价格： | 【●】元/股 | | 预计发行日期： | 【●】年【●】月【●】日 | | 拟上市的证券交易所： | 深圳证券交易所 | | 发行后总股本： | 不超过13,676万股 | | | 本次发行前公司股东对所持股份的流通限制和自愿锁定的承诺： | | | （一）控股股东、实 ...